2 papers and 0 clinical trials exploring esketamine as a treatment for equity and ethics.
Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.
Full Esketamine profileEquity and ethics in psychedelic research is a vital and complex topic, addressing the need for fair access and representation in clinical trials, as well as the stewardship of traditional knowledge. The involvement of Indigenous communities, who have historically used these substances, must be safeguarded against exploitation as the field matures.
Full Equity and Ethics profileNo clinical trials have been tagged with both Esketamine and Equity and Ethics yet.
Trials are continuously being added as new studies are registered.